European Patent Office

ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
금요일, 4월 12, 2024
UCLA, Congress, Sale, European Patent Office, Rutgers University, Chronic obstructive pulmonary disease, Outline of health sciences, Alopecia areata, Eosinophilic bronchitis, Safety, Skin, Drug development, European Patent Convention, Research, EASI, MD, Trial of the century, COPD, KOL, ADS, DHODH, Patent, Data, Patient, Liver, Dupilumab, Translational medicine, International Examiner, Harvard Medical School, ASLN, TREK, AA, Associate, Clinical trial, Emergency medicine, EPO, SAN, Contract research organization, Pharmaceutical industry

Cash used in operations for the fourth quarter of 2023 was $7.6 million compared to $12.0 million in the same period in 2022.

Key Points: 
  • Cash used in operations for the fourth quarter of 2023 was $7.6 million compared to $12.0 million in the same period in 2022.
  • Research and development expenses were $9.6 million in the fourth quarter of 2023 compared to $10.7 million in the fourth quarter of 2022.
  • General and administrative expenses were $3.2 million in the fourth quarter of 2023 compared to $2.7 million in the fourth quarter of 2022.
  • Net loss attributable to stockholders for the fourth quarter of 2023 was $13.5 million compared to a net loss of $14.5 million for the fourth quarter of 2022.

Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
화요일, 4월 30, 2024
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Education, PFS, Abbreviated New Drug Application, European Patent Office, Experiment, Breast, NET, ASCO, RCC, Associate, Translation, European Medicines Agency, Hearing, PIN, Drug development, European Patent Convention, Metastasis, Conference, Liver disease, ADC, Stada Arzneimittel, Tablet, Baylor College of Medicine, Distinguishing, Therapy, NHT, Calendar, BIRC, Huntsman Cancer Institute, OS, Dean (education), Docetaxel, PKMYT1, Checkmate, Prostate cancer, ITT, EPO, USP1, University, PARP, Immunotherapy, Superior, PLK4, Patent, Royalty payment, Patient, Society, Acquisition, Translational research, Neoplasm, Share repurchase, Annual general meeting, Baylor University

Exelixis’ 2024 net product revenues guidance range includes the impact of a U.S. wholesale acquisition cost increase of 2.2% for both CABOMETYX and COMETRIQ effective on January 1, 2024.

Key Points: 
  • Exelixis’ 2024 net product revenues guidance range includes the impact of a U.S. wholesale acquisition cost increase of 2.2% for both CABOMETYX and COMETRIQ effective on January 1, 2024.
  • Based upon cabozantinib-related net product revenues generated by Exelixis’ collaboration partners during the quarter ended March 31, 2024, Exelixis earned $39.6 million in royalty revenues.
  • In January, Exelixis announced the appointments of Mary C. Beckerle, Ph.D., and S. Gail Eckhardt, M.D., to the Exelixis Board of Directors, effective January 5, 2024.
  • Exelixis management will discuss the company’s financial results for the first quarter of 2024 and provide a general business update during a conference call beginning at 5:00 p.m.

ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio

Retrieved on: 
월요일, 3월 11, 2024
Therapy, European Patent Office, UBC, University, Patent, University of British Columbia, IP Australia, PMN, Japan Patent Office, PROMIS, Patient, Neuroscience

The United States Patent and Trademark Office also recently granted US Patent 11,905,317 directed to immunogenic compositions of matter that are being developed for treating AD.

Key Points: 
  • The United States Patent and Trademark Office also recently granted US Patent 11,905,317 directed to immunogenic compositions of matter that are being developed for treating AD.
  • Protection for the immunogenic compositions of matter has also been obtained in Japan, Korea, India and Australia.
  • Further, patent applications were also recently allowed in the U.S. and Japan for two other Aβ targets.
  • “We are building a fortress of intellectual property protection around our novel approach to targeting toxic misfolded proteins to treat neurodegenerative diseases and these newly allowed patents validate that innovation in important geographies around the world,” stated Neil Warma, Chief Executive Officer of ProMIS Neurosciences.

Windtree Therapeutics Announces Issuance of New Pure SERCA2a Activator Patent

Retrieved on: 
목요일, 11월 16, 2023
European Patent Office, Therapy, Ageing, Windtree Therapeutics, Heart, Patient, Heart failure, European Patent Convention, Diagnosis, Patent, Family, Hospital, PURE, Pharmaceutical industry

3805243, providing composition of matter patent coverage for the pure SERCA2a Activator class of drug candidates.

Key Points: 
  • 3805243, providing composition of matter patent coverage for the pure SERCA2a Activator class of drug candidates.
  • The pure SERCA2a Activators are one of two families of preclinical drug candidates that act on SERCA2a in the Company’s pipeline.
  • The new European patent, titled: “ANDROSTANE DERIVATIVES WITH ACTIVITY AS PURE OR PREDOMINANTLY PURE STIMULATORS OF SERCA2A FOR THE TREATMENT OF Heart Failure,” provides patent protection until October 9, 2039 for the family of compounds with the pure SERCA2a mechanism of action.
  • Windtree believes activation of SERCA2a represents a potentially important advancement in heart failure treatment for patients,” said Craig Fraser, CEO of Windtree Therapeutics.

Altamira Therapeutics Announces European Patent Office Decision to Grant for Patent Application Covering Intranasal Betahistine

Retrieved on: 
금요일, 11월 10, 2023
European Patent Office, Therapy, Betahistine, Patient, European, Intellectual property, European Patent Convention, EPO, RNA, Patent, Pharmaceutical industry

November 10, 2023 -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that it has received an “Intention to Grant” notice from the European Patent Office (EPO) for its patent application titled “Intranasal Composition Comprising Betahistine” (designated as European Patent 3698791).

Key Points: 
  • November 10, 2023 -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that it has received an “Intention to Grant” notice from the European Patent Office (EPO) for its patent application titled “Intranasal Composition Comprising Betahistine” (designated as European Patent 3698791).
  • The application is a continuation of the previously granted European Patent 3474850 and upon issuance, is expected to remain valid until February 2038.
  • Combined, these two patents will provide key intellectual property protection for the Company's intranasal betahistine program (AM-125) in Europe.
  • “We are very pleased with the continued expansion of our patent portfolio covering the intranasal betahistine program,” commented Thomas Meyer, Altamira Therapeutics’ founder, Chairman and CEO.

The European Patent Office (EPO) Rules in Favor of Mara and AO3 on Validity of DSM Patent EP3530740

Retrieved on: 
월요일, 11월 27, 2023
Vitamins, Supplements, Manufacturing, Other Manufacturing, Health, Fitness & Nutrition, European Patent Convention, EPO, European Patent Office, DSM, AO3, DHA, Patent, Dietary supplement

Mara Renewables Corporation, and its manufacturing partner Algal Omega-3 (AO3) announced today that the European Patent Office (EPO), Opposition Division, has ruled in favor of Mara regarding the validity of DSM’s patent EP3530740, titled “Thraustochytrids, fatty acid compositions, and methods of making and uses thereof.”

Key Points: 
  • Mara Renewables Corporation, and its manufacturing partner Algal Omega-3 (AO3) announced today that the European Patent Office (EPO), Opposition Division, has ruled in favor of Mara regarding the validity of DSM’s patent EP3530740, titled “Thraustochytrids, fatty acid compositions, and methods of making and uses thereof.”
    The EPO panel decided the DSM patent as granted is not valid and that its scope must be significantly narrowed.
  • As a result, the microbial oils claimed by the patent are now limited to those containing at least 60% DHA in the triglyceride fraction, up from a previous limit of at least 50% DHA.
  • “We are pleased with the decision of the EPO opposition division.
  • We will also look to enforce our own intellectual property in a responsible manner.

Cybin Reports Second Quarter Financial Results and Recent Business Highlights

Retrieved on: 
수요일, 11월 15, 2023
Biotechnology, FDA, Other Health, Health, General Health, Pharmaceutical, Mental Health, Other Science, Research, Science, Clinical Trials, Food and Drug Administration, Indian stock exchange, Depression, Safety, NYSE, Tryptamine, Acquisition, DMT, Food, DSM-IV codes, Completeness, European Patent Office, Warrant, Initiate, Acceleration, Exercise, Model Business Corporation Act, NEO, Data, Patient, European Patent Convention, Anxiety, MADRS, Phase, Mental health, Patent, Inc., Offering, MDD, Pharmaceutical industry, Security (finance), Medical imaging, Unit

Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation 2.0 psychedelic treatment options, today reported unaudited financial results for its second quarter ended September 30, 2023, and recent business highlights.

Key Points: 
  • Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation 2.0 psychedelic treatment options, today reported unaudited financial results for its second quarter ended September 30, 2023, and recent business highlights.
  • “We have made enormous progress during the past quarter, with ample momentum to carry us through year-end and into 2024.
  • Announced unprecedented positive Phase 2 interim data for CYB003, the Company’s proprietary deuterated psilocybin analog, in major depressive disorder (“MDD”).
  • Cash-based operating expenses totaled C$12.5 million for the quarter ended September 30, 2023, compared to C$11.3 million, in the prior year quarter, of which C$2.1 and C$2.0 million were one-time costs, respectively.

Darling Ingredients' health brand Rousselot receives U.S. Patent for gelatin technology that improves soft gel capsule stability and efficacy

Retrieved on: 
월요일, 12월 4, 2023
NYSE, European Patent Office, DAR, Cross-linking, European Patent Convention, EPO, Nutrient, Patent, Gelatin, 3D printing, Rousselot

11795489B2 to its health brand Rousselot, securing Rousselot's intellectual property rights for StabiCaps™, a specialized gelatin that improves the formulation and stability of soft gel capsules to enhance the release of active ingredients, including medications.

Key Points: 
  • 11795489B2 to its health brand Rousselot, securing Rousselot's intellectual property rights for StabiCaps™, a specialized gelatin that improves the formulation and stability of soft gel capsules to enhance the release of active ingredients, including medications.
  • StabiCaps addresses crosslinking, a common challenge in the dissolution of soft gel capsules that results in slower or incomplete release of nutrients or pharmaceutical ingredients contained within the capsule.
  • "StabiCaps is an essential innovation for soft gel capsule manufacturers because gelatin is a primary ingredient," said Pierre-Albert Thomas, Rousselot Functional Ingredients Director.
  • "With this new patent, soft gel manufacturers in the U.S. can unlock the benefits of StabiCaps gelatin technology to produce high quality soft gel capsules with longer shelf stability and improved efficacy for customers."

Anixa Biosciences Announces European Patent on Ovarian Cancer Vaccine Technology

Retrieved on: 
월요일, 11월 27, 2023
European Patent Office, SAN, National Cancer Institute, Menopause, European Patent Convention, EPO, Ovarian cancer, Vaccine, Cancer, Partnership, Patent, Pharmaceutical industry, Cleveland Clinic

SAN JOSE, Calif., Nov. 27, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its partner, Cleveland Clinic, has received an "Intention to Grant" notice from the European Patent Office ("EPO") for the patent application titled "Ovarian Cancer Vaccines."

Key Points: 
  • SAN JOSE, Calif., Nov. 27, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its partner, Cleveland Clinic, has received an "Intention to Grant" notice from the European Patent Office ("EPO") for the patent application titled "Ovarian Cancer Vaccines."
  • Dr. Amit Kumar, Chairman and CEO of Anixa, stated, "Having recently been granted a U.S. patent for this novel ovarian cancer vaccine technology, we are delighted to receive the EPO's intention-to-grant notice, as a European patent would extend protection of the technology to additional potential markets."
  • The patent was invented by the late Dr. Vincent Tuohy, Dr. Suparna Mazumder, and Dr. Justin Johnson of Cleveland Clinic.
  • Anixa exclusively licensed the technology from Cleveland Clinic and is developing the technology in partnership with the not-for-profit, multispecialty academic medical center.

EQS-News: Heidelberg Pharma Secures Patent for the Use of its ADC Technology Platform

Retrieved on: 
목요일, 12월 14, 2023
European Patent Office, Safety, European Patent Convention, Spacecraft, HPHA, ATAC, Amanitin, EPO, Research, Patent, FSE, Gesellschaft mit beschränkter Haftung

Ladenburg, Germany, 15 November 2023 – Heidelberg Pharma AG (FSE: HPHA) today announced that its subsidiary Heidelberg Pharma Research GmbH has been granted a patent covering site-specific ATAC conjugates by the European Patent Office (EPO).

Key Points: 
  • Ladenburg, Germany, 15 November 2023 – Heidelberg Pharma AG (FSE: HPHA) today announced that its subsidiary Heidelberg Pharma Research GmbH has been granted a patent covering site-specific ATAC conjugates by the European Patent Office (EPO).
  • Site-specific ATAC conjugates comprise a genetically engineered antibody to which Heidelberg Pharma’s proprietary amatoxin payloads can be coupled via specific linkers.
  • The European patent also covers a method for the synthesis of such conjugates as well as their use in the treatment of diseases.
  • Professor Andreas Pahl, Chief Scientific Officer of Heidelberg Pharma, comments: "We are very pleased that this patent has been granted, as it protects essential aspects of our ATAC technology, as e.g.